Trial Profile
A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2018
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Grifols
- 11 Jan 2016 Protocol amendment has been done in primary endpoints. Trial focus has been changed from TU & AR to AR as reported by ClinicalTrials.gov record.
- 15 May 2014 New trial record